Reuters Market Eye - Sun Pharmaceutical Industries gains more than 6 percent.
Heads towards biggest single-day gain since April 9.
Credit Suisse says Sun has received a Form 483 from the U.S. FDA on a Gujarat facility.
FDA's Form 483 is a letter that notifies company of objectionable conditions.
Traders say low chances of an import alert.
Credit Suisse notes the Form 483 given to Sun contained "no data integrity issues."
Also Read
Says chances of an import alert are "low."
Ranbaxy Laboratories , which is in the process of being acquired by Sun Pharma, is also up 5.5 percent.
Sun said on Sept. 12 the FDA inspected ints plant, but expected "no material impact."
A Sun spokesman did not immediately respond to request for comment.
(Reporting by Abhishek Vishnoi)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
